Literature DB >> 31234645

Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.

Ferdinando De Vita1, Christophe Borg2, Gabriella Farina3, Ravit Geva4, Iris Carton5, Hera Cuku6, Ran Wei7, Kei Muro8.   

Abstract

Aim: This subgroup analysis of the RAINBOW study evaluated the efficacy and safety of ramucirumab in patients with gastric cancer/gastroesophageal junction adenocarcinoma who received prior trastuzumab therapy. Patients & methods: Of adult patients enrolled in the RAINBOW study, 39 had received prior trastuzumab therapy. Of these, 20 patients were treated with ramucirumab plus paclitaxel and 19 patients with placebo plus paclitaxel within the RAINBOW trial.
Results: Overall survival was longer with ramucirumab plus paclitaxel (11.4 months; 95% CI: 7.0-17.9) versus placebo plus paclitaxel (7.0 months; 95% CI: 3.4-14.6), hazard ratio: 0.68 (0.33-1.41); p = 0.30. Longer progression-free survival, higher objective response were observed in ramucirumab combination group.
Conclusion: Ramucirumab plus paclitaxel demonstrated efficacy benefits with manageable safety profile in a subgroup of patients pretreated with trastuzumab. Clinical trial registration number: NCT01170663.

Entities:  

Keywords:  gastric cancer; HER-2 inhibitor; VEGFR-2 inhibitor; prior trastuzumab; ramucirumab plus paclitaxel; targeted therapy

Mesh：

Substances：

Year:  2019        PMID： 31234645     DOI： 10.2217/fon-2019-0243

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  11 in total

1.  Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway.

Authors:  Qian Xie; Jing Wang; Wenwen Wu; Ye Zhao
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.

Authors:  Sena Valcarcel; Javier Gallego; Paula Jimenez-Fonseca; Marc Diez; Eva Martínez de Castro; Raquel Hernandez; Virginia Arrazubi; Ana Custodio; Juana María Cano; Ana Fernández Montes; Ismael Macias; Laura Visa; Aitana Calvo; Rosario Vidal Tocino; Nieves Martínez Lago; María Luisa Limón; Mónica Granja; Mireia Gil; Paola Pimentel; Lola Macia-Rivas; Carolina Hernández Pérez; Montserrat Mangas; Alfonso Martín Carnicero; Paula Cerdà; Lucía Gomez Gonzalez; Francisco Garcia Navalon; Mª Dolores Mediano Rambla; Marta Martin Richard; Alberto Carmona-Bayonas
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-30       Impact factor: 4.322

Review 3.  The current management and biomarkers of immunotherapy in advanced gastric cancer.

Authors:  Xiaojing Chang; Xiaohui Ge; Yufeng Zhang; Xiaoying Xue
Journal:  Medicine (Baltimore)       Date:  2022-05-27       Impact factor: 1.817

4.  High expression of PIG11 correlates with poor prognosis in gastric cancer.

Authors:  Juan Gu; Shu Zhang; Xin He; Sufang Chen; Yan Wang
Journal:  Exp Ther Med       Date:  2021-01-22       Impact factor: 2.447

5.  A Network Pharmacology Approach for Uncovering the Antitumor Effects and Potential Mechanisms of the Sijunzi Decoction for the Treatment of Gastric Cancer.

Authors:  Pengpeng Ding; Yutong Guo; Canghai Wang; Jianhong Chen; Chunmei Guo; Hong Liu; Qi Shi
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-12       Impact factor: 2.650

Review 6.  Emerging Trends in Immunotherapy for Cancer.

Authors:  Alok K Mishra; Amjad Ali; Shubham Dutta; Shahid Banday; Sunil K Malonia
Journal:  Diseases       Date:  2022-09-06

7.  Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.

Authors:  Almudena Cotes Sanchís; Javier Gallego; Raquel Hernandez; Virginia Arrazubi; Ana Custodio; Juana María Cano; Gema Aguado; Ismael Macias; Carlos Lopez; Flora López; Laura Visa; Marcelo Garrido; Nieves Martínez Lago; Ana Fernández Montes; María Luisa Limón; Aitor Azkárate; Paola Pimentel; Pablo Reguera; Avinash Ramchandani; Juan Diego Cacho; Alfonso Martín Carnicero; Mónica Granja; Marta Martín Richard; Carolina Hernández Pérez; Alicia Hurtado; Olbia Serra; Elvira Buxo; Rosario Vidal Tocino; Paula Jimenez-Fonseca; Alberto Carmona-Bayonas
Journal:  PLoS One       Date:  2020-07-31       Impact factor: 3.240

Review 8.  Precision medicine in gastric cancer.

Authors:  Patrizia Bonelli; Antonella Borrelli; Franca Maria Tuccillo; Lucrezia Silvestro; Raffaele Palaia; Franco Maria Buonaguro
Journal:  World J Gastrointest Oncol       Date:  2019-10-15

Review 9.  Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies.

Authors:  Julita Machlowska; Jacek Baj; Monika Sitarz; Ryszard Maciejewski; Robert Sitarz
Journal:  Int J Mol Sci       Date:  2020-06-04       Impact factor: 5.923

Review 10.  Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  World J Gastrointest Oncol       Date:  2021-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.